KRAS and non-small cell lung carcinoma: Similar to the osimertinib example in Figure 1, the UK’s National Health Service (NHS) moved forward with an accelerated patient access for sotorasib, a breakthrough KRAS inhibitor for the KRAS G12C non-small cell lung cancer (NSCLC) subtype.